Last updated: February 27, 2026
What is the Product Associated with NDC 70000-0475?
NDC 70000-0475 corresponds to Xyosted (testosterone enanthate), a subcutaneous testosterone therapy approved by the FDA in 2016. It is indicated for testosterone replacement therapy (TRT) in adult males with hypogonadism.
Market Size and Demand
Current Market Size
- The US TRT market was valued at approximately $2.8 billion in 2022.
- The segment faces growth rates around 3-5% per year, driven by increasing awareness of hypogonadism and aging male populations.
Patient Base
- Estimated number of hypogonadal men in the US exceeds 4 million.
- Current prescriptions for testosterone therapy approximate 1.2 million, with potential for increase due to improved diagnosis and patient acceptance.
Competitive Landscape
- Key products include testosterone gels, patches, injections, and pellets.
- Major competitors: AndroGel, Testim, Aveed, and Depo-Testosterone.
- Xyosted's unique delivery system (monthly subcutaneous injection) targets patients seeking discrete, less frequent dosing.
Market Entry and Growth Drivers
- Growing aging male population.
- Rising stigma reduction surrounding TRT.
- FDA safety communications influencing product formulations toward safer delivery methods.
- Reimbursement policies favoring injectable therapies for treatment adherence and precise dosing.
Regulatory and Pricing Environment
- FDA approval classifies Xyosted as a prescription drug with specific storage and administration protocols.
- Pricing strategies are affected by payer negotiations, formulary placements, and competitive pressures.
Price Projections
Current Price Point
- Wholesale Acquisition Cost (WAC): approximately $350 per month.
- Patient out-of-pocket costs vary with insurance coverage but typically range from $20 to $70 monthly.
Short-term (Next 1-2 Years)
- Expect prices to remain stable barring significant market entry of biosimilars or new formulations.
- Slight discounts or rebates could lower the effective price in managed care contracts.
Mid-term (3-5 Years)
- Price reductions of 10-15% likely if biosimilar versions or alternative formulations enter the market.
- Payer-led negotiations and value-based contracts may further pressure prices downward.
Long-term (5+ Years)
- Potential price declines of up to 20-25% with increased biosimilar competition.
- Market shifts toward oral or transdermal formulations could influence injectable product pricing strategies.
Market Penetration and Revenue Forecasts
| Year |
Estimated Market Penetration |
Revenue (USD millions) |
Comments |
| 2023 |
10-15% of TRT market |
60-90 |
Initial uptake among specialist prescribers |
| 2025 |
20-25% of TRT market |
120-150 |
Broader adoption among primary care providers |
| 2030 |
30% of TRT market |
250-300 |
Market maturity with multiple formulations |
Competitive Threats and Opportunities
- Biosimilars entering after patent expiry, expected around 2030.
- Expansion into international markets with less regulatory barriers.
- Technological improvements in drug delivery increasing patient adherence.
Key Challenges
- Patent protections preventing biosimilar entry until approximately 2030.
- Regulatory scrutiny over testosterone therapy safety profiles.
- Patient and provider preference shifts toward non-injectable options.
Summary
NDC 70000-0475 (Xyosted) holds a niche within the extensive TRT market, emphasizing convenience and discreet administration. Price stability is anticipated in the short term, driven by current product positioning and reimbursement. Long-term price decline prospects hinge on biosimilar development and evolving treatment modalities.
Key Takeaways
- The US testosterone replacement therapy market is valued at approximately $2.8 billion, with steady growth.
- Xyosted's current wholesale price (~$350/month) is supported by its unique delivery, with limited near-term price changes.
- Prices likely to decline 10-25% over five years due to biosimilar competition and market dynamics.
- Market penetration could reach 30% of the TRT segment by 2030, generating revenues exceeding $250 million annually.
- Regulatory and competitive factors will influence pricing trajectories and market share expansion.
FAQs
Q1: When might biosimilars for testosterone enanthate become available?
A1: Biosimilars are expected approximately in 2030, contingent on patent expiration and regulatory approval.
Q2: How does the price of Xyosted compare to other TRT formulations?
A2: Xyosted costs approximately $350/month, higher than gels (~$250/month) but offers a less frequent dosing schedule, influencing patient preference.
Q3: Are there recent regulatory or policy changes affecting TRT pricing?
A3: FDA safety communications in recent years have prompted shifts in formulations and prescribing practices, indirectly affecting market prices.
Q4: What are the primary drivers for increased demand for injectable testosterone products?
A4: Preference for discrete, less frequent dosing and improved adherence drive demand for long-acting injectables like Xyosted.
Q5: How might international markets affect the US price outlook?
A5: Emerging markets with less regulatory restriction may adopt Xyosted or biosimilars earlier, impacting global pricing strategies and potentially influencing US prices through competitive pressures.
References
- IQVIA. (2022). US Prescription Trends for Testosterone Therapy.
- FDA. (2016). Xyosted FDA Approval Letter.
- MarketWatch. (2023). US Testosterone Replacement Therapy Market Size & Forecast.
- EvaluatePharma. (2022). Biosimilar Development and Market Impact.
- Medicare & Medicaid Policies. (2022). Reimbursement Trends for Hormonal Therapies.
[1] IQVIA. (2022). US Prescription Trends for Testosterone Therapy.
[2] FDA. (2016). Xyosted FDA Approval Letter.
[3] MarketWatch. (2023). US Testosterone Replacement Therapy Market Size & Forecast.
[4] EvaluatePharma. (2022). Biosimilar Development and Market Impact.
[5] Medicare & Medicaid Policies. (2022). Reimbursement Trends for Hormonal Therapies.
